HER2 is a member of the human epidermal growth factor receptor (EGFR) family. Its positive expression can be found in various cancers, including breast cancer, gastric cancer, ovarian cancer, esophageal cancer, lung cancer, and bile duct cancer. HER2 forms homodimers by itself or heterodimers with other members of the EGFR family. This dimerization can autophosphorylate and/or transphosphorylate specific tyrosine kinases in its intracellular region, thereby activating downstream signaling pathways and promoting tumor cell proliferation, survival, and metastasis.
1Trial Title:A randomized, open-label, controlled, multicenter Phase III clinical study to evaluate the efficacy and safety of Hemay022 in combination with an aromatase inhibitor in postmenopausal patients with HER2+/ER+ advanced breast cancer previously treated with a trastuzumab-containing regimen.
Target Population： Patients with HER2+/ER+ advanced breast cancer
Clinical Project Description： A multicenter, open-label, controlled, randomized Phase III clinical trial to evaluate the efficacy of Hemay022 in combination with an aromatase inhibitor (exemestane or letrozole) in patients with ER-positive and HER2-positive advanced breast cancer, based on investigator-assessed progression-free survival (PFS).
